Friday, May 10 2024
12:00 PM – 07:00 PM ET - Exhibit Hall
1775: Gene-Edited Hematopoietic Stem Cells to Enable Next-Generation CAR-T Cell Therapy for the Treatment of AML
Julia Etchin - PhD
Vor Biopharma
Disclosures: J. Etchin: 1; Commercial Interest i.e. Company X; Vor Biopharma. 1; What was received? i.e. Honorarium; Employment, Salary, Equity. 1; For what role? i.e. Speaker; Employment.
Related Abstract